Previous close | 85.88 |
Open | 85.83 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 84.87 - 85.86 |
52-week range | 57.55 - 86.60 |
Volume | |
Avg. volume | 691,908 |
Market cap | 8.587B |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | 22.33 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.60 (0.70%) |
Ex-dividend date | 01 Jul 2024 |
1y target est | N/A |
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.